肿瘤细胞治疗研究
英文原题：Chimeric antigen receptor T-cell therapy for T-ALL and AML.
非B细胞急性白血病是一个涵盖T细胞急性淋巴细胞白血病（T-ALL）和急性髓系白血病（AML）的术语。
非B细胞急性白血病是一个涵盖T细胞急性淋巴细胞白血病（T-ALL）和急性髓系白血病（AML）的术语。目前，针对难治性或复发性（R/R）非B细胞急性白血病的现有治疗疗效有限。在这种情况下，嵌合抗原受体（CAR）-T细胞疗法可能是治疗非B细胞急性白血病的一种有前景的方法，鉴于其在B细胞急性淋巴细胞白血病（B-ALL）中取得的令人鼓舞的结果。然而，针对T-ALL的自相残杀、恶性污染、T细胞发育不全，以及针对AML的特异性抗原选择和复杂的微环境，仍然是CAR-T疗法在T-ALL和AML患者临床实施中的重大挑战。因此，针对T-ALL的靶向CD5和CD7以及针对AML的CD123、CD33和CLL1的CAR-T细胞设计在临床试验中显示出有前景的疗效和安全性特征。在这篇综述中，我们总结了非B细胞急性白血病的特征、CAR的发展、CAR靶点及其治疗非B细胞急性白血病的疗效。
Non-B-cell acute leukemia is a term that encompasses T-cell acute lymphoblastic leukemia (T-ALL) and acute myeloid leukemia (AML). Currently, the therapeutic effectiveness of existing treatments for refractory or relapsed (R/R) non-B-cell acute leukemia is limited. In such situations, chimeric antigen receptor (CAR)-T cell therapy may be a promising approach to treat non-B-cell acute leukemia, given its promising results in B-cell acute lymphoblastic leukemia (B-ALL). Nevertheless, fratricide, malignant contamination, T cell aplasia for T-ALL, and specific antigen selection and complex microenvironment for AML remain significant challenges in the implementation of CAR-T therapy for T-ALL and AML patients in the clinic. Therefore, designs of CAR-T cells targeting CD5 and CD7 for T-ALL and CD123, CD33, and CLL1 for AML show promising efficacy and safety profiles in clinical trials. In this review, we summarize the characteristics of non-B-cell acute leukemia, the development of CARs, the CAR targets, and their efficacy for treating non-B-cell acute leukemia.
MEMBER ACCOUNT
登录成功会直接打开下一页。
